TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

Clinical trial NCT01485991 · COMPLETED

Trial details

NCT number

NCT01485991

Sponsor

Janssen R&D Ireland

Status

COMPLETED

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2012-02-01

Primary completion

2014-04-01

Enrollment

771

View on ClinicalTrials.gov